-
Mashup Score: 0Final Overall Survival Results from the PROpel Phase 3 Trial in First-line Therapy for mCRPC - Fred Saad - 10 month(s) ago
Fred Saad joins Alicia Morgans in a discussion on the final overall survival data from the PROpel trial, a randomized controlled trial aimed to address the first-line mCRPC question in patients who have not been treated with a novel hormonal agent in the mCRPC setting. Patients were randomized to receive abiraterone and prednisone or abiraterone and olaparib. The trial’s primary endpoint was…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 4PARP Inhibitor Plus Androgen Receptor Signaling Inhibitor Combinations: Will This Be The Future of mCRPC First-Line Therapy? - 10 month(s) ago
PARPi plus androgen receptor signaling inhibitor, metastatic castrate-resistant prostate cancer (mCRPC), PROpel, MAGNITUDE, TALAPRO-2, imaging-based progression-free survival, PARPi plus an ARSI in the first-line treatment setting for mCRPC.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
PARP inhibitor + AR signaling inhibitor combinations: Will this be the future of #mCRPC first-line therapy? #LibraryResource @RKSayyid @UofT and @zklaassen_md @GACancerCenter discuss data from the #PROpel, #MAGNITUDE, and #TALAPRO2 trials on UroToday > https://t.co/Lel4jqTXoV https://t.co/7xe3Vo9AtU
-
-
Mashup Score: 0Final Overall Survival Results from the PROpel Phase 3 Trial in First-line Therapy for mCRPC - Fred Saad - 11 month(s) ago
Fred Saad joins Alicia Morgans in a discussion on the final overall survival data from the PROpel trial, a randomized controlled trial aimed to address the first-line mCRPC question in patients who have not been treated with a novel hormonal agent in the mCRPC setting. Patients were randomized to receive abiraterone and prednisone or abiraterone and olaparib. The trial’s primary endpoint was…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Exciting news in #mCRPC research! Join @CaPsurvivorship @DanaFarber and Fred Saad, MD, FRCS @chumontreal as they discuss the #PROpel trial's final OS data, showing a 7.4-month improvement in pts who received abiraterone and olaparib. #WatchNow > https://t.co/WTPVLZ4Wa5 https://t.co/GXY8hlfNQ0
-
-
Mashup Score: 5
ASCO 2023 health-related quality of life PROpel trial, PROpel trial pain outcomes for mCRPC, PROpel mCRPC abiraterone + olaparib versus abiraterone + placebo in the phase III PROpel trial.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Health-related quality of life and pain outcomes for patients with #mCRPC who received abiraterone and olaparib vs Abi and placebo in the phase III #PROpel trial. Presented by @AarmstrongDuke @DukeCancer. #ASCO23 written coverage by @RKSayyid @UofT > https://t.co/Fm46a2XSJE @ASCO https://t.co/9JhxdGJp1v
-
-
Mashup Score: 0LYNPARZA® (Olaparib) plus Abiraterone Approved in the US for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer - 11 month(s) ago
LYNPARZA® (olaparib) in combination with abiraterone and prednisone or prednisolone, deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC), LYNPARZA plus abiraterone.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
LYNPARZA® (olaparib) + abiraterone approved in the US for the treatment of BRCA-mutated #mCRPC. Approval based on a subgroup analysis of the PIII #PROpel trial #ReadNow details on UroToday > https://t.co/dZpX6CTT9E @AstraZeneca @Merck @AarmstrongDuke @LYNPARZAhcp @FoundationATCG https://t.co/ArsYH5u82d
-
-
Mashup Score: 6FDA approves olaparib with abiraterone and prednisone - 11 month(s) ago
FDA approves olaparib with abiraterone and prednisone (or prednisolone) for BRCA-mutated metastatic castration-resistant prostate cancer
Categories: Latest Headlines, UrologyTweet-
And it’s finally out: FDA just approves olaparib+abiraterone for mCRPC pra with BRCA mut. #propel f/ ODAC recs. More news with #talapro2 #magnitude soon @FDAOncology ? @neerajaiims @AarmstrongDuke @DrChoueiri @GUONCGarciaJA @AarmstrongDuke @DrRanaMcKay https://t.co/0cmIbKj5ud
-
-
Mashup Score: 1Final Overall Survival Results from the PROpel Phase 3 Trial in First-line Therapy for mCRPC - Fred Saad - 12 month(s) ago
Fred Saad joins Alicia Morgans in a discussion on the final overall survival data from the PROpel trial, a randomized controlled trial aimed to address the first-line mCRPC question in patients who have not been treated with a novel hormonal agent in the mCRPC setting. Patients were randomized to receive abiraterone and prednisone or abiraterone and olaparib. The trial’s primary endpoint was…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Exciting news in #mCRPC research! Join @CaPsurvivorship @DanaFarber and Fred Saad, MD, FRCS @chumontreal as they discuss the #PROpel trial's final OS data, showing a 7.4-month improvement in pts who received abiraterone and olaparib. #WatchNow > https://t.co/WTPVLZ4Wa5 https://t.co/ceiss6i6mt
-
-
Mashup Score: 5AUA 2023: Prostate Specific Antigen Analyses in PROpel: Abiraterone and Olaparib Vs Abiraterone and Placebo as First-line Therapy for mCRPC - 1 year(s) ago
AUA 2023 PSA analysis from PROpel, phase 3 trial of abiraterone + olaparib versus abiraterone + placebo as first-line treatment of mCRPC, homologous recombination repair gene mutation (HRRm).
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
PSA analyses in #PROpel: abiraterone and olaparib vs abiraterone and PBO as first-line therapy for #mCRPC. Presented by Fred Saad, MD, FRCS @chumontreal. #AUA23 written coverage by @zklaassen_md @GACancerCenter on UroToday > https://t.co/RP0DwdGaRZ @AmerUrological https://t.co/2bPzKprWVA
-
-
Mashup Score: 0AUA Congress 2023 - 1 year(s) ago
UroToday – GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Excited for #AUA23 presentation by Fred Saad, MD, FRCS @chumontreal on Prostate-specific antigen analyses in #PROpel: abiraterone and olaparib vs abiraterone and PBO as 1st-line therapy for #mCRPC! Written coverage to follow on UroToday > https://t.co/PfABzVll5Y @AmerUrological https://t.co/oPbwq7wsYl
-
-
Mashup Score: 0AUA Congress 2023 - 1 year(s) ago
UroToday – GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Excited for #AUA23 presentation by Fred Saad, MD, FRCS @chumontreal on Prostate-specific antigen analyses in #PROpel: abiraterone and olaparib vs abiraterone and PBO as 1st-line therapy for #mCRPC! Written coverage to follow on UroToday > https://t.co/PfABzVll5Y @AmerUrological https://t.co/eqT3IUIImg
-
Exciting news in #mCRPC research! Join @CaPsurvivorship @DanaFarber and Fred Saad, MD, FRCS @chumontreal as they discuss the #PROpel trial's final OS data, showing a 7.4-month improvement in pts who received abiraterone and olaparib. #WatchNow > https://t.co/WTPVLZ4Wa5 https://t.co/VDqSzAOCvi